© 2025 WGLT
A public service of Illinois State University
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations

NIH funding cuts could have 'devastating impact' on medical advancements, Chicago researchers say

Attending a news conference Monday on the impact that cuts in research funding from the NIH could have on medical institutions across the state were (from left): Allyson Hansen, CEO and executive director of the Illinois Medical District; Dr. Scott Andre Oakes; U.S. Sen. Dick Durbin; Dr. Rachel Caskey; and Dr. Robert Higgins.
Cindy Hernandez
/
Chicago Sun-Times
Attending a news conference Monday on the impact that cuts in research funding from the NIH could have on medical institutions across the state were (from left): Allyson Hansen, CEO and executive director of the Illinois Medical District; Dr. Scott Andre Oakes; U.S. Sen. Dick Durbin; Dr. Rachel Caskey; and Dr. Robert Higgins.

The National Institutes of Health under President Donald Trump announced this month that it was cutting payments covering overhead costs for research institutions that receive its grants. Schools like UIC and UC rely on the grants, and caps could create huge budget gaps.

Dr. Rachel Caskey has dedicated her career to finding ways to improve maternal child health, but a halt in federal funding could threaten years of research.

“Our UIC Maternal Health Research Center of Excellence is using NIH funding to eliminate maternal morbidity and mortality and promote maternal health equity across Illinois,” said Caskey, professor and head of the Department of Medicine at University of Illinois Chicago. “The impact of this Center of Excellence will improve the lives of women and children in communities across our city, state and we hope the country.”

Caskey joined other researchers and U.S. Sen. Dick Durbin, D-Ill., at a news conference Monday at the Illinois Medical District to discuss the impact that cuts in research funding from the National Institutes of Health could have on medical institutions across the state.

In the 2024 fiscal year, UIC received more than 1,000 NIH-funded awards. With expenditures of $200 million, $63 million were indirect costs, Caskey said.

The NIH, under President Donald Trump, announced this month that it was cutting payments toward overhead costs for research institutions that receive its grants. The new policy would cap “indirect costs” of research at 15%, and could leave universities with major budget gaps. Hundreds of medical centers and universities have long relied on such reimbursements at rates of 60% or more for such expenses as facility maintenance, conducting studies and paying utilities.

RELATED

Chicago-area federal workers on edge as Trump guts agencies: ‘It’s devastating’

Anger, chaos, confusion as federal workers face mass layoffs

“The proposed cap would cut indirect cost recovery by more than 70% at the University of Illinois Chicago, which could have devastating impact on our ability to conduct life-saving research,” Caskey said.

Last week, Illinois Attorney General Kwame Raoul along with 21 other Democratic attorneys general announced a lawsuit to block the Trump administration from cutting off funding.

The NIH is under “political attack,” but medical research is critical for finding cures to diseases and saving lives, said Dr. Scott Andre Oakes, professor of pathology and vice dean for clinical science research at the University of Chicago.

“We need to remember that diseases are purple and medical research is purple,” Oakes said, referring to health research being a nonpartisan issue. “All Americans are susceptible to disease, and all of us benefit from the new treatments that come from the research supported by the NIH. Withdrawing or decreasing funding for the NIH will stall our collective efforts to find new cures and leave patients without hope.”

At Rush University there are more than 270 active clinical trials underway, but the proposed cuts could limit researchers’ ability to make medical advancements, said Dr. Robert Higgins, president and chief academic officer at the university.

“While we seem like this is an exercise in trimming the fat from a fiscal standpoint, at the national level, it is in fact cutting into our ability to advance treatments, to developing new therapies and pharmaceuticals that ultimately will help us understand diseases and save lives,” Higgins said. “It will eliminate that hope that our patients need and deserve.”

For now, universities and medical institutions are able to continue their work, but the threat remains.

“As of today, the message has been operations as usual, but we’re all watching, of course, quite anxiously to see where this might head,” Caskey said. “Researchers, clinicians and patients are extremely anxious. We’re getting questions across the board, and it’s trickling down to patients asking, particularly those who may have participated in a clinical trial or a family member has, and now they’re concerned, will this finish? What could happen?”

Research is able to continue because of the lawsuit blocking the policy from going into effect, Durbin said. “This is being fought in courts, and that’s why there may be a temporary reprieve. I hope it goes beyond temporary, but this research should not be interrupted,” he said.

Cindy Hernandez is a general assignment reporter for the Chicago Sun-Times. She previously worked for WGLT as a reporting and social media intern.